---
figid: PMC6770909__cancers-11-01382-g001
figtitle: Redifferentiation of thyroid cancer
organisms:
- Homo sapiens
- Rattus norvegicus
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC6770909
filename: cancers-11-01382-g001.jpg
figlink: /pmc/articles/PMC6770909/figure/cancers-11-01382-f001/
number: F1
caption: Redifferentiation of thyroid cancer. MAPK (mitogen-activated protein kinase)
  (RAS/RAF/MEK) and PI3K/AKT/mTOR are key signaling pathways in thyroid cancer pathogenesis.
  Signaling cascades can be blocked by new targeted therapies. The crosstalk between
  MAPK and PI3K through RAS is shown and represents a tumor escape mechanism from
  known multi-kinase inhibitors and selective inhibitors of BRAF. PI3K-AKT pathway
  activation leads to suppression of NIS (sodium/iodide symporter) glycosylation and
  surface translocation. The inhibition of mTOR promotes redifferentiation of thyroid
  cancer cells by upregulation of NIS mRNA and protein expression through increased
  transcription of TTF1. Another important positive regulator of NIS expression is
  PTEN. TSH (thyroid stimulating hormone) signals through the heterotrimeric G-protein
  complex, and through activation of cAMP increases transcription of the NIS gene.
  Aberrant activation of the MAPK signaling pathway inhibits PIGU expression and NIS
  basolateral transport. PTTG1 and PBF overexpression results in decreased NIS levels
  in thyroid cancer.
papertitle: 'Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation
  Therapies, Management, and Novel Therapies.'
reftext: Mohamed Aashiq, et al. Cancers (Basel). 2019 Sep;11(9):1382.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9692508
figid_alias: PMC6770909__F1
figtype: Figure
redirect_from: /figures/PMC6770909__F1
ndex: db541eb9-dec8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6770909__cancers-11-01382-g001.html
  '@type': Dataset
  description: Redifferentiation of thyroid cancer. MAPK (mitogen-activated protein
    kinase) (RAS/RAF/MEK) and PI3K/AKT/mTOR are key signaling pathways in thyroid
    cancer pathogenesis. Signaling cascades can be blocked by new targeted therapies.
    The crosstalk between MAPK and PI3K through RAS is shown and represents a tumor
    escape mechanism from known multi-kinase inhibitors and selective inhibitors of
    BRAF. PI3K-AKT pathway activation leads to suppression of NIS (sodium/iodide symporter)
    glycosylation and surface translocation. The inhibition of mTOR promotes redifferentiation
    of thyroid cancer cells by upregulation of NIS mRNA and protein expression through
    increased transcription of TTF1. Another important positive regulator of NIS expression
    is PTEN. TSH (thyroid stimulating hormone) signals through the heterotrimeric
    G-protein complex, and through activation of cAMP increases transcription of the
    NIS gene. Aberrant activation of the MAPK signaling pathway inhibits PIGU expression
    and NIS basolateral transport. PTTG1 and PBF overexpression results in decreased
    NIS levels in thyroid cancer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KDR
  - FLT1
  - FLT4
  - RET
  - PDGFRB
  - PDGFRA
  - ERBB2
  - ERBB3
  - TSHR
  - NPL
  - GNAS
  - GNAL
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - PTTG1
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - PTTG1IP
  - ZNF395
  - PIGU
  - TP53INP2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - TTF1
  - NKX2-1
  - PAX8
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - Ret
  - Tshr
  - Pik3cg
  - Pten
  - Pttg1
  - Braf
  - Akt1
  - Pigu
  - Mtor
  - Ephb1
  - Ttf1
  - Nkx2-1
  - Pax8
  - Pvr
  - reticulated
  - reti
  - rets
  - her
  - Hesr
  - na
  - gs
  - Tie
  - Ras85D
  - InR
  - ras
  - Ras64B
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Akt
  - PIG-U
  - Tor
  - Erk7
  - rl
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Dsor1
  - Mtk
  - kita
  - ngfra
  - ret
  - her2
  - her3
  - tshr
  - rab1ab
  - ptenb
  - pttg1
  - braf
  - si:dkey-222f8.3
  - pigu
  - mtor
  - ttf1.1
  - pax8
  - Sulfatinib
  - Vandetanib
  - Na
  - Lapatinib
  - Sorafenib
  - Lenvatinib
  - Dabrafenib
  - Vemurafenib
  - Selumetinib
  - Temsirolimus
  - Trametinib
  - Everolimus
  - Cancer
  - Lung cancer
---
